Iris Biotechnologies (PRIVATE.IRSB)

Overall impact
B (74)

Commentary

Iris Biotechnologies is a strong overall performer. With a 'B' rating of 73.9 for overall impact (87th percentile compared to all companies), Iris Biotechnologies ranks 18th out of 103 industry peers, behind MyMD Pharmaceuticals, electroCore, Endologix and 14 others, and ahead of Waters, Alphatec, Biolase and 82 others. On top material causes for Iris Biotechnologies's industry (Healthcare Equipment), Iris Biotechnologies performs well in Child and Maternal Health (91.0 score), Child and Maternal Health (82.0), Racial Justice and Civil Rights (95.7) and 3 other causes where it received an 'A' score and performs poorly in Disease Eradication (37.1 score) and Sanitation Access (33.0).
Impact
Cause PRIVATE.IRSB
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
California, United States
Share classes
PRIVATE.IRSB
Description
Iris Biotechnologies Inc develops solutions for the detection and monitoring of monogenic and complex genomic diseases. It has developed a technology platform used for the diagnosis and treatment of patients with breast cancer, neurological disorders, heart diseases, diabetes, and other gene-related metabolic problems. Its products pipeline includes CancerChip, PrenatalChip, Integrated Blood Test, IVF applications, NeuroChip, MetabolicChip, CardioChip, and Chips for veterinary, agricultural, environmental, and other applications.
Material causes
Ethos considers the following causes material for Iris Biotechnologies, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.